AMOXIL ORAL SUSP Rx
Generic Name and Formulations:
Amoxicillin (as trihydrate) 250mg/5mL, 400mg/5mL; bubble-gum flavor.
Dr. Reddy's Laboratories, Inc.
Indications for AMOXIL ORAL SUSP:
Susceptible infections including ear/nose/throat (ENT), lower respiratory tract, skin and skin structure, genitourinary tract, acute uncomplicated gonorrhea.
Mild to moderate ENT, skin, or genitourinary: 500mg every 12hrs or 250mg every 8hrs. Lower respiratory or severe ENT, skin, or genitourinary: 875mg every 12hrs or 500mg every 8hrs. Gonorrhea: 3g once. Severe renal impairment (CrCl <30mL/min): 875mg tabs not recommended; CrCl 10–30mL/min: 250–500mg every 12hrs; CrCl <10mL/min: 250–500mg every 24hrs (give additional doses during and after hemodialysis).
For treating acute otitis media: The AAP recommends 80–90mg/kg per day in divided doses (note: this is not an FDA-approved dose). Do not exceed recommended adult dose. >40kg: dose as adults. Neonates and infants ≤3months: max 30mg/kg per day in divided doses every 12hrs. >3months: Mild to moderate ENT, skin, or genitourinary: 25mg/kg per day in divided doses every 12hrs or, 20mg/kg per day in divided doses every 8hrs. Lower respiratory or severe ENT, skin, or genitourinary: 45mg/kg per day in divided doses every 12hrs or, 40mg/kg per day in divided doses every 8hrs. Gonorrhea: ≤2yrs: not recommended; >2yrs: 50mg/kg with 25mg/kg probenecid once. Renal dysfunction: not recommended.
Cephalosporin, imipenem, other allergy or mononucleosis: not recommended. Monitor blood, renal, and hepatic function in long-term use. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Potentiated by probenecid. May cause false (+) glucose test with Clinitest, Benedict's or Fehling's soln.
GI upset, hypersensitivity reactions (eg, urticaria, rash, Stevens-Johnson syndrome, anaphylaxis), hyperactivity, blood dyscrasias.
Caps—500; Susp 250mg/5mL—100mL, 150mL; Susp 400mg/5mL—100mL; Drops 50mg/mL—30mL
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Electroacupuncture May Help Reduce Opioid Use in Chronic Musculoskeletal Pain
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Pharmacologically Induced Headache Accompanied by Dilated Cephalic Vessels
- IV Lidocaine May Be Safe, Efficacious for Pediatric Status Migraine
- Gray Matter Changes in Migraine Associated With Clinical Characteristics